jcm-logo

Journal Browser

Journal Browser

Head and Neck Cancer: Clinical Diagnostics and Treatments

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Otolaryngology".

Deadline for manuscript submissions: closed (30 April 2026) | Viewed by 674

Special Issue Editor


E-Mail Website
Guest Editor
Otolaryngology & Head and Neck Medical Center, Stockholm, Sweden
Interests: head and neck surgery; skull base; sentinel node

Special Issue Information

Dear Colleagues,

Head and neck cancer is a collective term that includes several types of cancers—with different diagnostic and treatment modalities—categorized by the area in which they originate. Depending on its site, the cancer interferes with e.g., chewing/swallowing (oral cavity, pharynx), voice (larynx), breathing (sinuses and nose cavity), salivation (salivary glands), etc. Thus, both the cancer itself and treatments interfere with function and sometimes cosmetics.

Globally it is estimated that approximately 900,000 new cases of head and neck cancer occur annually (2018). The most common type is the squamous cell carcinoma. The overall 5-year survival rate of all patients with head and neck cancer is approximately 60 percent but with considerable variations in survival depending on the primary site of the cancer. The most important parameter for survival is early detection.

For almost two centuries surgery was the only treatment option. In today’s multidisciplinary treatment, often aiming at organ preservation, surgery is frequently combined with not only radiotherapy but also with cytotoxic drugs, targeted drugs, and immunotherapy. Improved diagnostics (e.g., MRI, PET, sentinel node technique) have refined both the delineation of the cancer itself and the detection of eventual spread to regional lymph nodes or extra-regional metastases. To be noted is that even a new disease has emerged in the past 20-25 years—HPV-associated cancers of the tongue base and the tonsils.

To further increase survival rates, both surgical and drug-induced therapies must be improved through international clinical and basic science cooperation. The aim of this Special Issue is to gather new knowledge to improve treatment of head and neck patients.

Prof. Dr. Matti Anniko
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • treatment
  • surgery
  • chemotherapy
  • immunotherapy
  • diagnostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 359 KB  
Article
Nasal Sublesional Bevacizumab Injections as Adjuvant Treatment for Diffuse Sinonasal Exophytic Papillomas
by Anna Penella, Adriana Michavila, Marta Fulla, Elisabet Leiva Badosa, Aina Brunet, Maria Foglia-Fernández and Xavier González-Compta
J. Clin. Med. 2026, 15(2), 723; https://doi.org/10.3390/jcm15020723 - 15 Jan 2026
Viewed by 422
Abstract
Background/Objectives: Diffuse sinonasal exophytic papillomas (DSNEPs) are rare entities, with similarities to recurrent respiratory papillomatosis (RRPs). DSNEP treatment is usually based on surgical excision, but the recurrence rate is high. Bevacizumab injections have been increasingly used as an adjuvant option for RRP, but [...] Read more.
Background/Objectives: Diffuse sinonasal exophytic papillomas (DSNEPs) are rare entities, with similarities to recurrent respiratory papillomatosis (RRPs). DSNEP treatment is usually based on surgical excision, but the recurrence rate is high. Bevacizumab injections have been increasingly used as an adjuvant option for RRP, but their role in DSNEP treatment remains unknown. The current study describes the preliminary experience, safety profile, and exploratory outcomes of sublesional bevacizumab injections following surgical excision. Methods: We undertook a retrospective, single-centre study of a cohort of patients diagnosed with DSNEP between 2011 and 2018. All patients were treated with surgical excision and sublesional bevacizumab injections. The effect of bevacizumab was evaluated using a severity score developed to quantify lesion size and the extent of affected areas in each patient. Results: Seven patients diagnosed with DSNEP were treated. All patients were male, with a median age at diagnosis of 42 years [38–44.5]. Human papillomavirus (HPV) DNA was detected in all patients: HPV-11 in six cases (85.7%) and HPV-6 in one case (14.3%). Bevacizumab was injected into the submucosa of their surgical sites. The median follow-up was 55.5 months [40.85–82.73]. Most patients (85.72%) presented recurrence, with a median of 3 years [1.5–4]. A statistically significant reduction in the severity score was observed (p = 0.017), although this finding cannot be attributed solely to bevacizumab due to study design limitations. No relevant complications were reported. Conclusions: Nasal sublesional bevacizumab injections were well tolerated and feasible as an adjuvant approach to DSNEP. Larger prospective studies are needed to confirm its safety and assess its potential benefit. Full article
(This article belongs to the Special Issue Head and Neck Cancer: Clinical Diagnostics and Treatments)
Show Figures

Figure 1

Back to TopTop